10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2021 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 23, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Operating Activities: | |||
| Net income | $ 6,201 | 89 | 5,364 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 329 | 288 | 255 |
| Amortization expense | 1,721 | 1,192 | 1,149 |
| Stock-based compensation expense | 635 | 643 | 636 |
| Deferred income taxes | (116) | (214) | (2,098) |
| Net (gain) loss from equity securities | 610 | 1,662 | (1,241) |
| Acquired in-process research and development expenses | 177 | 5,856 | 4,251 |
| In-process research and development impairment | 0 | 0 | 800 |
| Write-downs for slow-moving and excess raw material and work in process inventory | 121 | 40 | 547 |
| Other | 1,217 | 250 | 279 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | 313 | (1,171) | (218) |
| Inventories | 11 | (195) | (95) |
| Prepaid expenses and other | (42) | (214) | (307) |
| Accounts payable | (118) | 80 | (61) |
| Income taxes payable | (364) | (778) | 272 |
| Accrued liabilities | 689 | 640 | (389) |
| Net cash provided by operating activities | 11,384 | 8,168 | 9,144 |
| Investing Activities: | |||
| Purchases of marketable debt securities | (3,517) | (20,315) | (30,455) |
| Proceeds from sales of marketable debt securities | 730 | 23,239 | 7,523 |
| Proceeds from maturities of marketable debt securities | 2,180 | 9,479 | 22,398 |
| Acquisitions, including in-process research and development, net of cash acquired | (1,402) | (25,742) | (4,251) |
| Purchases of equity securities | (380) | (455) | (1,773) |
| Capital expenditures | (579) | (650) | (825) |
| Other | (163) | (171) | (434) |
| Net cash used in by investing activities | (3,131) | (14,615) | (7,817) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 0 | 8,184 | 0 |
| Proceeds from issuances of common stock | 169 | 256 | 209 |
| Repurchases of common stock | (546) | (1,583) | (1,749) |
| Repayments of debt and other obligations | (4,750) | (2,500) | (2,750) |
| Payment of dividends | (3,605) | (3,449) | (3,222) |
| Other | (145) | (138) | (122) |
| Net cash (used in) provided by financing activities | (8,877) | 770 | (7,634) |
| Effect of exchange rate changes on cash and cash equivalents | (35) | 43 | (2) |
| Net change in cash and cash equivalents | (659) | (5,634) | (6,309) |
| Cash and cash equivalents at beginning of period | 5,997 | 11,631 | |
| Cash and cash equivalents at end of period | 5,338 | 5,997 | 11,631 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 979 | 951 | 982 |
| Income taxes paid | 2,509 | 2,639 | 1,793 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |